Medical and Economic Evaluation for Intermediate-risk Prostate Cancer

Inclusion Criteria:

• age between 18 and 80 years;

• life expectancy of greater than 10 years;

• prostate adenocarcinoma histologically proven;

• prostate cancer has to be of intermediate-risk based on at least one of the threefollowing criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance statusECOG 0-2.

• the patient has to be the beneficiary of the social security system (order n° 2006-477from April 26th 2006);

• the signed consent form.

Exclusion Criteria:

• PSA level > 20;

• Gleason > 7;

• clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3Awon't be an exclusion criterion);

• prostate volume > 60 cc;

• pelvic lymph nodes involvement at dissection or imaging (ADP > 1.5 cm);

• concurrent hormone therapy;

• the presence of distant metastasis (M1);

• history of abdominal or pelvic irradiation;

• history of prostate resection in the previous 6 months and/or not allowing theimplantation of markers;

• history of uncontrolled cancer and/or treated since less than 5 years (excepting thebasal-cell carcinoma);

• urinary discomfort with an IPSS (International Prostate Symptom Score) > 15 (withoutalpha-blocking);

• inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;

• other undergoing study that may interfere with the present study;

• patient under legal protection measure.